Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 29, 2021 | Series A | $50M | 1 |
Versant Ventures
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
Yes | Series A |